- Increasing Protein Production with Novel Cell-Ess Titer Boost without Affecting the Metabolic ProfilePosted 4 days ago
- Continuous Processing Optimization with Smarter ToolsPosted 5 days ago
- Cool Tool – Generation of Neural Stem Cells from AlphaSTEM Cultured Pluripotent Stem CellsPosted 6 days ago
- Synergizing Transient and Stable Protein Expression for Accelerated Biotherapeutic DevelopmentPosted 1 week ago
- Cell Culture Dish Top Ten Ask the Expert Sessions and Podcasts of 2016Posted 2 weeks ago
- A Look at the Current State of Continuous BioprocessingPosted 2 weeks ago
- Cool Tool – Biomek i-Series – Next Generation Automated Workstations Specifically Designed to Meet Evolving WorkflowsPosted 2 weeks ago
- Filling Industry Gaps with Dedicated Cell Therapy Fluid Transfer SetsPosted 3 weeks ago
- Cell Culture Monitoring – A Critical Component for Quality by Design in Cell TherapyPosted 3 weeks ago
- The Top 15 Cell Culture Dish Cool Tools Features in 2016Posted 3 weeks ago
Current Advances and Challenges in the Use of Cord Blood Hematopoietic Stem/Progenitor Cells
Stem/Progenitor cells from umbilical cord blood (UCB) have many advantages as a source of hematopoietic cells for transplantation. Studies have shown that cord blood cells are an effective alternative to bone marrow for transplantation and lack the HLA restrictions of bone marrow derived cells. Development of cord blood cells for therapy is dependent on the development of successful blood-derived free and xeno-free culture methods that enable the ex vivo expansion of clinical grade cells.
A recent review article by Kita et al. entitled “Cord Blood Derived Hematopoietic Stem/Progenitor Cells: Current Challenges in Engraftment, Infection, and Ex Vivo Expansion” details the current advances and the challenges in the establishment of defined culture conditions for the expansion of cord blood stem cells .
“The limited number of human stem cells/human progenitor cells is the major obstacle in blood transplantation. Efficient methods are needed to obtain a larger quantity of primitive cells from umbilical cord blood (UCB). For this reason, developing simple and realistic protocols for the industrial expansion of primitive cells in UCB is essential. …With well-defined ex vivo expansion protocols, UCB is likely to “rock” the area of blood cell transplantation.”
The article further details the advancement of growth factor cocktails (notch signaling ligand) and alternative approaches (such as the use of aryl hydrocarbon receptor antagonists) that may advance the efficient ex vivo expansion of these cells. Other advances, such as the use of defined, recombinant, xeno-free, blood-free culture medium components, such as transferrin and human albumin (2), further enable the development of the defined clinical protocols required for clinical application.
- Kita, K., J. Lee, C. Finnerty, and D. Herndon, Cord blood-derived hematiooiteic stem/progenitor cells: Current challenges in engraftment, infection, and ex vivo expansion. 2011. Stem Cells Intl. 2011 (Article ID 276193,) 8 pages. Link: http://www.sage-hindawi.com/journals/sci/2011/276193/